Herein, we establish the clonal aspects of single and multiple PIK3CAmut, enhance our understanding of how multiple PIK3CAmut impact ability of other cellular signaling pathways to influence anti-tumor responses of patients with HR+/HER2– metastatic BC to PI3K inhibition, and provide justification for new rational therapeutic combination approaches. This evidence concerns the gene ERBB2 and breast cancer.